CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Kintara Therapeutics, Inc. - KTRA CFD

0.39
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* 0.38
1-Year Change* -91.22%
Day's Range* 0.38 - 0.45
52 wk Range 0.09-0.95
Average Volume (10 days) 977.26K
Average Volume (3 months) 50.77M
Market Cap 8.41M
P/E Ratio -100.00K
Shares Outstanding 80.81M
Revenue N/A
EPS -0.56
Dividend (Yield %) N/A
Beta 1.12
Next Earnings Date Feb 9, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 29, 2023 0.39 0.01 2.63% 0.38 0.46 0.38
Nov 10, 2023 0.38 0.00 0.00% 0.38 0.65 0.38
Nov 9, 2023 0.38 -0.02 -5.00% 0.40 0.40 0.37
Nov 8, 2023 0.39 -0.02 -4.88% 0.41 0.41 0.39
Nov 7, 2023 0.41 -0.01 -2.38% 0.42 0.42 0.38
Nov 6, 2023 0.40 -0.03 -6.98% 0.43 0.43 0.38
Nov 3, 2023 0.41 0.00 0.00% 0.41 0.46 0.40
Nov 2, 2023 0.38 -0.10 -20.83% 0.48 0.48 0.38
Nov 1, 2023 0.48 -0.22 -31.43% 0.70 0.70 0.46
Oct 31, 2023 0.73 -0.22 -23.16% 0.95 1.08 0.71
Oct 30, 2023 3.72 -0.04 -1.06% 3.76 3.88 3.62
Oct 27, 2023 4.11 0.14 3.53% 3.97 4.32 3.97
Oct 26, 2023 4.08 -0.10 -2.39% 4.18 4.34 4.08
Oct 25, 2023 3.87 -0.31 -7.42% 4.18 4.18 3.74
Oct 24, 2023 4.10 -0.18 -4.21% 4.28 4.28 4.08
Oct 23, 2023 4.17 0.22 5.57% 3.95 4.32 3.74
Oct 20, 2023 3.97 0.00 0.00% 3.97 4.30 3.97
Oct 19, 2023 4.26 0.08 1.91% 4.18 4.47 4.17
Oct 18, 2023 4.04 0.36 9.78% 3.68 4.07 3.68
Oct 17, 2023 3.69 0.07 1.93% 3.62 3.70 3.60

Kintara Therapeutics, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 0 0 0 0 0
Total Operating Expense 38.166 9.19824 8.3985 11.1747 8.32083
Selling/General/Admin. Expenses, Total 9.757 4.51452 4.73644 3.82753 3.34785
Research & Development 27.909 3.63002 3.66206 7.34714 4.97298
Operating Income -38.166 -9.19824 -8.3985 -11.1747 -8.32083
Interest Income (Expense), Net Non-Operating -0.132 0.07233 0.47646 0.03635 0.23907
Net Income Before Taxes -38.298 -9.12592 -8.04822 -11.1383 -8.08176
Net Income After Taxes -38.298 -9.12592 -8.04822 -11.1383 -8.08176
Net Income Before Extra. Items -38.298 -9.12592 -8.04822 -11.1383 -8.08176
Net Income -38.298 -9.12592 -8.04822 -11.1383 -8.08176
Total Adjustments to Net Income -3.206 -0.00862 -0.08043 -0.17624 -0.79045
Income Available to Common Excl. Extra. Items -41.504 -9.13453 -8.12865 -11.3146 -8.87222
Income Available to Common Incl. Extra. Items -41.504 -9.13453 -8.12865 -11.3146 -8.87222
Diluted Net Income -41.504 -9.13453 -8.12865 -11.3146 -8.87222
Diluted Weighted Average Shares 25.886 10.444 2.57469 2.08614 1.20471
Diluted EPS Excluding Extraordinary Items -1.60334 -0.87462 -3.15714 -5.42367 -7.36462
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -1.58402 -0.77373 -3.15714 -5.42367 -7.36462
Other, Net -0.12619
Unusual Expense (Income) 0.5 1.0537
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 0 0 0 0 0
Total Operating Expense 5.358 5.895 5.971 6.697 6.605
Selling/General/Admin. Expenses, Total 1.884 1.993 2.178 2.666 2.762
Research & Development 3.474 3.902 3.793 4.031 3.843
Unusual Expense (Income) 0 0 0 0 0
Operating Income -5.358 -5.895 -5.971 -6.697 -6.605
Interest Income (Expense), Net Non-Operating 0.002 0.002 0.005 -0.035 -0.03
Net Income Before Taxes -5.356 -5.893 -5.966 -6.732 -6.635
Net Income After Taxes -5.356 -5.893 -5.966 -6.732 -6.635
Net Income Before Extra. Items -5.356 -5.893 -5.966 -6.732 -6.635
Net Income -5.356 -5.893 -5.966 -6.732 -6.635
Total Adjustments to Net Income -0.002 -0.002 -2.464 -0.004 -0.008
Income Available to Common Excl. Extra. Items -5.358 -5.895 -8.43 -6.736 -6.643
Income Available to Common Incl. Extra. Items -5.358 -5.895 -8.43 -6.736 -6.643
Diluted Net Income -5.358 -5.895 -8.43 -6.736 -6.643
Diluted Weighted Average Shares 49.128 48.529 34.281 32.441 29.273
Diluted EPS Excluding Extraordinary Items -0.10906 -0.12147 -0.24591 -0.20764 -0.22693
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.10906 -0.12147 -0.24591 -0.20764 -0.22693
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 11.793 2.85108 4.02519 7.04644 7.87073
Cash and Short Term Investments 10.537 2.3924 3.71876 5.972 6.58601
Cash & Equivalents 10.537 2.3924 3.71876 5.972
Total Receivables, Net 0.0094 0.02619 0.03952 0.0766
Prepaid Expenses 0.756 0.35558 0.28025 1.03493 1.20812
Other Current Assets, Total 0.5 0.0937
Total Assets 13.543 2.93814 4.03726 7.07486 7.91102
Intangibles, Net 0.00211 0.01206 0.02841 0.04029
Total Current Liabilities 2.78 2.67492 2.06973 1.63852 1.30436
Payable/Accrued 2.219 2.01106 1.74452 1.47809 1.18231
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.561 0.66387 0.32521 0.16043 0.12205
Total Liabilities 2.962 2.67492 2.06973 1.63963 1.3325
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.182 0 0.00112 0.02814
Total Equity 10.581 0.26321 1.96753 5.43522 6.57852
Preferred Stock - Non Redeemable, Net 14.931 4.80343 4.97783 6.42541 6.42541
Common Stock 0.033 0.01146 0.00384 0.02297 0.01451
Additional Paid-In Capital 106.821 56.6241 50.9547 43.1775 36.6653
Retained Earnings (Accumulated Deficit) -111.225 -61.1969 -53.9901 -44.2119 -36.5479
Other Equity, Total 0.021 0.02118 0.02118 0.02118 0.02118
Total Liabilities & Shareholders’ Equity 13.543 2.93814 4.03726 7.07486 7.91102
Total Common Shares Outstanding 32.74 11.4579 3.83936 2.29667 1.45096
Total Preferred Shares Outstanding 0.279 0.92714 0.95214 1.15964 1.15964
Cash 6.58601
Other Long Term Assets, Total 1.6 0.08494
Property/Plant/Equipment, Total - Net 0.15
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 10.093 14.998 20.108 11.793 16.588
Cash and Short Term Investments 8.839 14.064 19.339 10.537 15.718
Cash & Equivalents 8.839 14.064 19.339 10.537 15.718
Total Receivables, Net 0.007
Prepaid Expenses 1.254 0.934 0.769 0.756 0.363
Other Current Assets, Total 0 0 0 0.5 0.5
Total Assets 12.798 17.718 22.343 13.543 18.853
Property/Plant/Equipment, Total - Net 0.105 0.12 0.135 0.15 0.165
Intangibles, Net 0
Other Long Term Assets, Total 2.6 2.6 2.1 1.6 2.1
Total Current Liabilities 3.24 3.438 3.001 2.78 2.533
Payable/Accrued 2.782 2.895 2.51 2.219 1.645
Notes Payable/Short Term Debt 0 0 0 0 0.503
Other Current Liabilities, Total 0.458 0.543 0.491 0.561 0.385
Total Liabilities 3.412 3.616 3.18 2.962 2.735
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.172 0.178 0.179 0.182 0.202
Total Equity 9.386 14.102 19.163 10.581 16.118
Preferred Stock - Non Redeemable, Net 12.554 12.801 13.675 14.931 19.726
Common Stock 0.049 0.049 0.048 0.033 0.032
Additional Paid-In Capital 127.67 126.781 125.074 106.821 100.828
Retained Earnings (Accumulated Deficit) -130.908 -125.55 -119.655 -111.225 -104.489
Other Equity, Total 0.021 0.021 0.021 0.021 0.021
Total Liabilities & Shareholders’ Equity 12.798 17.718 22.343 13.543 18.853
Total Common Shares Outstanding 49.306 49.013 47.974 32.74 31.764
Total Preferred Shares Outstanding 0.296 0.296 0.297 0.279 0.901
Accumulated Depreciation, Total -0.015
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line -38.298 -9.12592 -8.04822 -11.1383 -8.08176
Cash From Operating Activities -18.86 -7.92752 -6.32743 -9.85085 -8.01907
Amortization 0.002 0.00995 0.01635 0.02453 0.01668
Non-Cash Items 22.057 0.70174 0.56965 0.68542 0.52439
Changes in Working Capital -2.651 0.48671 1.13479 0.57751 -0.47838
Cash From Investing Activities 0.964 0 -0.01265 -0.02096
Capital Expenditures -0.008 0 -0.01265 -0.02096
Cash From Financing Activities 26.041 6.60116 4.07419 9.24948 8.46878
Financing Cash Flow Items -0.03 -0.025
Total Cash Dividends Paid -0.008 -0.00836 -0.00836 -0.00836 -0.00836
Issuance (Retirement) of Stock, Net 26.079 6.63452 4.08254 9.25784 8.47713
Net Change in Cash 8.145 -1.32636 -2.25324 -0.61402 0.42875
Cash Taxes Paid 0 0 0 0
Cash Interest Paid 0.03 0 0 0 0
Cash From Operating Activities 0.03
Other Investing Cash Flow Items, Total 0.972
Issuance (Retirement) of Debt, Net 0
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -17.215 -11.859 -5.966 -38.298 -31.566
Cash From Operating Activities -15.4 -10.177 -5.073 -18.86 -14.171
Cash From Operating Activities 0.045 0.03 0.015 0.03 0.015
Amortization 0 0 0 0.002 0.002
Non-Cash Items 2.308 1.672 0.839 22.057 20.891
Cash Taxes Paid 0 0
Cash Interest Paid 0 0.03 0
Changes in Working Capital -0.538 -0.02 0.039 -2.651 -3.513
Cash From Investing Activities 0 0 0 0.964 0.964
Capital Expenditures 0 -0.008 -0.008
Other Investing Cash Flow Items, Total 0 0 0 0.972 0.972
Cash From Financing Activities 13.702 13.704 13.875 26.041 26.533
Total Cash Dividends Paid -0.006 -0.004 -0.002 -0.008 -0.006
Issuance (Retirement) of Stock, Net 13.708 13.708 13.877 26.079 26.039
Issuance (Retirement) of Debt, Net 0 0 0 0 0.5
Net Change in Cash -1.698 3.527 8.802 8.145 13.326
Financing Cash Flow Items -0.03

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Kintara Therapeutics, Inc. Company profile

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Industry: Bio Therapeutic Drugs

9920 Pacific Heights Blvd, Suite 150
Suite 200
92121

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

ETH/USD

2,969.17 Price
+0.150% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,376.65 Price
+0.640% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.40

US100

17,594.40 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

0.49 Price
-0.390% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading